

**Remarks**

Applicants bring to the attention of the Examiner the preliminary amendment submitted by the Applicants on October 17, 2003 whereby claims 2 to 14 were cancelled without prejudice or disclaimer and the priority information for this application was updated. Applicants again request entry of the amendments contained in the preliminary amendment. Applicants reserve the right to file one or more divisional, continuation, or continuation-in-part applications directed to withdrawn or canceled subject matter disclosed in the application as originally filed.

In response to the Restriction Requirement, dated November 22, 2005, Applicants hereby elect Group I, directed to a method of treating an individual having an neuroectodermal tumor using a neuorectodermal tumor specific ligand fused to a cytotoxic moiety and a pharmaceutically acceptable carriers. Applicants have amended claim 1 and added new claims 15 to 28 directed to better define the invention and submit that the subject matter of the new claims is directed to the elected invention. Written support for these amendments can be found throughout the specification and in the original claims. Applicants therefore submit that no new matter has been added.


**Conclusions**

It is respectfully submitted that all claims are now in condition for allowance, early notice of which would be appreciated. Should the Examiner disagree, Applicants respectfully requests a telephonic or in-person interview with the undersigned attorney to discuss any remaining issues and to expedite the eventual allowance of the claims.

Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any necessary fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17, which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310.

Dated: **February 22, 2005**  
Morgan, Lewis & Bockius LLP  
Customer No. 09629  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
202-739-3000

Respectfully submitted,  
**Morgan, Lewis & Bockius LLP**

  
\_\_\_\_\_  
Robert Smyth  
Registration No. 50,801